The invention relates a cross-linked polymer obtainable by reacting a maltodextrin deriving from starch comprising amylose in the range from 25 to 50% expressed as dry weight relative to the dry weight of the starch and at least one cross-linking compound having a electropositive carbon atom selected from the group consisting of a dicarboxylic acid, dianhydride, carbonyldiimidazole, diphenylcarbonate, triphosgene, acylic dichloride, diisocyanate, diepoxide The polymer of the invention can be used for the encapsulation/inclusion/entrapment of an organic compound.

The present invention relates to the field of drug carrier systems and polymer therapeutics and diagnostics. It provides derivatized unimolecular polyols with a hydrophobic core moiety and a polyanionic, preferably, sulfated hydrophilic shell, N in particular to unimolecular hyperbranched sulfated polyglycerol micelles having a hydrophilic shell and a hydophrobic core. These may be used for the supramolecular encapsulation and transport of hydrophobic guest molecules into biological systems. The micelles can be applied as a drug carrier system for therapy and for diagnosis. They may also be therapeutic agents on their own. The invention also relates to preparation of said micelles.

This present invention relates to the carbon nanotubes as composites with materials such as elastomers, thermosets and thermoplastics or aqueous dispersions of open-ended carbon nanotubes with additives. A further feature of this invention relates to the development of a concentrate of carbon nanotubes with an elastomer wherein the concentrate can be further diluted with an elastomer and other polymers and fillers using conventional melt mixing equipment.

The present document describes a powder composition comprising a functionalized starch having a single helix V-structure and having a degree of substitution of at least 0.25, and a bioactive agent, forming an inclusion complex with said functionalized starch, where the bioactive agent is within the helix V-structure of the functionalized starch having a single helix V-structure. Also described are the functionalized starch having a single helix V-structure and having a degree of substitution of at least 0.25, methods of making the same and methods of using the same to manufacture the powder composition.

A metal-organic framework (MOF) having the function of controlling the release of guests is provided in which reversible release control is possible and release control can be rapidly performed and which is capable of accommodating the release of various guest molecules. The metal-organic framework comprises both an organic ligand having two or more functional groups (coordinating functional groups) capable of coordinating to a metal atom and metal ions that combine with the coordinating functional groups of the organic ligand, and has a structure in which one metal ion has combined with two or more of the coordinating functional groups to connect multiple molecules of the organic ligand. The metal-organic framework/Stimulus-responsive polymer composite was obtained by affixing a stimulus-responsive polymer to at least some of the surface of the metal-organic framework. The stimulus-responsive polymer may be affixed by bonding to the organic ligand.

This present invention relates to the carbon nanotubes as composites with materials such as elastomers, thermosets and thermoplastics or aqueous dispersions of open-ended carbon nanotubes with additives. A further feature of this invention relates to the development of a concentrate of carbon nanotubes with an elastomer wherein the concentrate can be further diluted with an elastomer and other polymers and fillers using conventional melt mixing equipment.

The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used to deliver the therapeutic agent and to treat various disorders. Both the polymer of the particulate composite and the complexing agent may be used to introduce functionality into the therapeutic composition. The invention also relates to a method of preparing a composition. The method combines a therapeutic agent, a polymer having host or guest functionality, and a complexing agent having guest or host functionality to form the therapeutic composition. The complexing agent forms an inclusion complex with the polymer. The invention also relates to a method of delivering a therapeutic agent. According to the method, a therapeutically effective amount of a therapeutic composition of the invention is administered to a mammal (e.g. person or animal) in recognized need of the therapeutic. Also disclosed are compounds having the formula:

##STR00001##

Acyclic CB[n]-type compounds, methods of making such compounds, and uses of the compounds. For example, these compounds can be used as nanocontainers to solubilize pharmaceutical agents. Also provided are compositions and methods of using them for therapy or prophylaxis of a wide variety of conditions for which therapy or prophylaxis is desirable.

The invention in suitable embodiments is directed to purified non-cage clathrin protein compositions. In one aspect, one or more purified non-cage clathrin protein composition, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues, forms a composition to repurpose at least one aspect of a medicament or use thereof when the medicament is formulated with the non-cage clathrin protein.

The invention in suitable embodiments is directed to using purified, non-cage clathrin protein for purposes of assisting in drug discovery and development. In one aspect, a tool composition, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more protein sequence, forms one or more type of tool for carrying out various elements and activities of drug discovery and development.